Ca²⁺ Channel Toolkit in Neuroendocrine Tumors

Alessandra Fiorio Pla^{a–c} Dimitra Gkika^{b, c}

^aDepartment of Life Science and Systems Biology, University of Torino, Turin, Italy; ^bInserm, U1003 – PHYCEL (Physiologie Cellulaire), Université de Lille, Lille, France; ^cLaboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, Villeneuve d'Ascq, France

Keywords

Neuroendocrine tumors · Ca²⁺ signals · Ion channels

Abstract

Neuroendocrine tumors (NET) constitute a heterogeneous group of malignancies with various clinical presentations and growth rates but a common origin in neuroendocrine cells located all over the body. NET are a relatively low-frequency disease mostly represented by gastroenteropancreatic (GEP) and bronchopulmonary tumors (pNET); on the other hand, an increasing frequency and prevalence have been associated with NET. Despite great efforts in recent years, the management of NET is still a critical unmet need due to the lack of knowledge of the biology of the disease, the lack of adequate biomarkers, late presentation, the relative insensitivity of imaging modalities, and a paucity of predictably effective treatment options. In this context Ca²⁺ signals, being pivotal molecular devices in sensing and integrating signals from the microenvironment, are emerging to be particularly relevant in cancer, where they mediate interactions between tumor cells and the tumor microenvironment to drive different aspects of neoplastic progression (e.g., cell proliferation and survival, cell invasiveness, and proangiogenic programs). Indeed, ion channels represent good potential pharmacological targets due to their loca-

tion on the plasma membrane, where they can be easily accessed by drugs. The present review aims to provide a critical and up-to-date overview of NET development integrating Ca²⁺ signal involvement. In this perspective, we first give an introduction to NET and Ca²⁺ channels and then describe the different families of Ca²⁺ channels implicated in NET, i.e., ionotropic receptors, voltage-dependent Ca²⁺ channels, and transient receptor potential channels, as well as intracellular Ca²⁺ channels and their signaling molecules.

© 2019 S. Karger AG, Basel

Introduction

Neuroendocrine tumors (NET) represent a variety of malignancies with a heterogeneous histology. They originate in neuroendocrine cells located all over the body [1]. The term neuroendocrine refers to the “neuro” (identified as presence of dense core granules) and “endocrine” properties (identified as the ability to secrete monoamine) of the cells composing the mass. NET are a relatively low-incidence disease (about 0.5% of the total estimated diagnosed tumors) but exhibit an increasing frequency and prevalence, with the most common being gastroenteropancreatic (GEP), bronchopulmonary (pNET), and thymus tumors and several uncommon localizations such as

the ovaries, heart, and ear [2, 3]. Although their classification is quite confusing, in general NET can be categorized into the following 2 different groups based on clinical behavior, histology, and proliferation rate: low-grade indolent tumors (well-differentiated cells) and high-grade aggressive carcinomas (poorly differentiated cells).

Well-differentiated NET express typical neuroendocrine markers such as chromogranin A (CgA) and synaptophysin (Syn); on the contrary, poorly differentiated NET cells present a sheet-like proliferation more typical of carcinomas with limited immunocytochemical staining patterns for neuroendocrine markers (diffuse expression of Syn and faint or focal staining for CgA). Up to 40% of NET contain elements of a nonneuroendocrine histology; by definition, the neuroendocrine component has to exceed 30% of the tumor to be called a NET; otherwise, it is classified as a mixed adenoneuroendocrine carcinoma [2]. Other useful markers are somatostatin receptors (SSR), whose identification and quantification by immunohistochemistry or imaging are very useful to identify and predict the response to somatostatin analogs [3].

The general treatment for low-grade tumors is surgical resection, while unresectable and symptomatic disease is treated with somatostatin analogs and/or interferon- α even though tumor regression with these agents is rare [2, 4, 5]. In contrast, etoposide/platinum-based chemotherapy is the mainstay of treatment for high-grade or metastatic NET. As an alternative, peptide receptor radionuclide therapy has been recently approved both in Europe and in US. Peptide receptor radionuclide therapy relies on the use of somatostatin receptor ligand conjugated with radioactive isotopes such as yttrium-90 and/or lutetium-177 for treatment purposes [6]. NET are also highly vascularized, and thus angiogenesis inhibitors such as sunitinib or VEGF inhibitors are good candidates for treatment [2].

Despite great efforts in recent years, the management of NET is still a critical unmet need due to the lack of knowledge of the biology of the disease, the lack of adequate biomarkers allowing identification of the primary tumor site or differentiation of tumor grading, late presentation, the relative insensitivity of imaging modalities, and a paucity of predictably effective treatment options [3].

Ca²⁺ Homeostasis Deregulation in Cancer

Accumulating evidence demonstrates that the development of several cancers, including NET, involves an altered Ca²⁺ homeostasis and aberrant ion channel ex-

pression [7, 8]. This is not surprising considering the multifaceted role of Ca²⁺ as a ubiquitous second messenger which is involved in the tuning of multiple fundamental cellular functions [9]. It has to be considered that the ubiquity of Ca²⁺ signals is not in antithesis with a specific role in a particular oncogenic mechanism. Each cell indeed possesses a Ca²⁺ machinery that enables the activation of Ca²⁺ signals of a particular amplitude, frequency and intracellular location. The presence of particular fingerprints allows Ca²⁺ to control specific cellular functions that may be altered during cancer progression [7, 10]. The intracellular Ca²⁺ concentration, i.e., [Ca²⁺]_i, is finely regulated and the different mechanisms involved in Ca²⁺ homeostasis are usually referred to as a “Ca²⁺ toolkit” and include Ca²⁺-permeable channels, pumps, and exchangers [11]. The concentration gradient between intracellular cytosolic free [Ca²⁺] (~100 nM) and Ca²⁺ in extracellular fluids (~1 mM) is very large compared to those of other ions, being about 1:10,000. This gradient is assured by several “on” and “off” mechanisms that finally result in Ca²⁺ signals that can be codified in amplitude and frequencies. With regard to the “on” mechanisms, [Ca²⁺]_i can increase via the following 2 different mechanisms: release from intracellular stores (mainly ER but also mitochondria or endolysosomes as an example) or entry from an extracellular medium via Ca²⁺-permeable ion channels opened on the plasma membrane thanks to the strong electrochemical gradient that promotes the influx of Ca²⁺ into the cell [11].

Ion channels therefore represent a good potential pharmacological target also due to their location on the plasma membrane, where they can be easily accessed by drugs. Since the first reports identifying the role of ion channels in cancer development [12–15], the field has undergone exponential development, giving rise to a large consensus in the scientific community to consider ion channels in cancer development as “oncochannelopathy” [16, 17]. Beside ion channels, altered Ca²⁺-regulated proteins have been also extensively investigated as a possible target to modulate cancer development [7].

A general classification of Ca²⁺ channels can be described on the basis of the gating mechanism. In this context the studies of electrical excitability of the 1950s and 1960s provided a good basis for classification into voltage-gated channels and ligand-gated channels. Voltage-gated Ca²⁺ channels comprise 3 voltage-gated calcium channel subfamilies, i.e., CaV1, CaV2, and CaV3, encoded by 10 genes [18]. The ligand-gated channel classification can be achieved according to the nature of the signaling molecule (ligand) that activated them (e.g., acetylcho-

line, glutamate, serotonin, or ATP). In recent years, intense studies have led to an exponential increase in the number of ion channel types and families thanks to the application of molecular biology techniques to the cloning of their gene [16]. In particular the cloning of transient receptor potential (TRP) ion channels gave rise to a whole new family of channels which are good candidates for mediated non-voltage gated Ca^{2+} signals. TRP channels include ion channels with a high selectivity for Ca^{2+} and potential constitutive activity (e.g., TRPV5 and TRPV6), as well as temperature-sensitive channels such as the cold sensor TRPM8 and the heat and capsaicin (hot chilly component)-sensitive TRPV1 [19]; different TRP channels are activated by second messengers and can promote a Ca^{2+} influx via store-operated Ca^{2+} entry (SOCE), which is activated in response to endoplasmic reticulum (ER) Ca^{2+} store depletion. In physiological conditions this is achieved by agonist-stimulated inositol 1,4,5-trisphosphate (IP3) generation and release of ER Ca^{2+} through the IP3 receptor (IP3R). In turn, Ca^{2+} release is detected by the ER Ca^{2+} sensor stromal interaction molecule 1 (STIM1). Upon Ca^{2+} store depletion, STIM1 proteins form clusters and subsequently interact with TRP channels proteins found at the plasma membrane, leading to activation of a Ca^{2+} influx [20]. Another important Ca^{2+} channel is calcium release-activated calcium channel protein 1 (ORAI1), which is involved in SOCE [21]. In particular, strong evidence has shown that, besides STIM1, also STIM2 is involved in ORAI1 activation under low-agonist, low-ER Ca^{2+} release by promoting STIM1 clustering in ER-PM junctions and thus increasing the assembly of the ORAI1-STIM1 complex and activation of SOCE [22, 23]. ORAI family of channels comprise another 2 related proteins, i.e., ORAI2 and ORAI3, which do not mediate SOCE (NSOCE) Ca^{2+} signals as homotetramers but can mediate SOCE Ca^{2+} signals in heteromeric channels composed of ORAI isoforms particularly in neurons where ORAI2 is likely to be the main candidate for SOCE [24–26].

In order to categorize all of the channels expressed at a cellular level, the term “channelome” has been reported in analogy with the widely accepted terms “genome,” “proteome,” and “metabolome,” and the branch of research focused on the study of ion channelomes has been referred to as “channelomic” [16].

In this regard identification of the channelome in specific cancer types is especially important, since its determination might help to set up strategies to specifically target cancer cells but not healthy tissues, in contrast to the most widely used chemotherapies which affect the

most rapidly proliferating cells. In addition, the tissue-specific location of these channels and their variable structure could render the treatment of oncochannelopathies possible without causing considerable side effects to other organs (i.e., liver, kidney, central nervous system, medulla etc.).

Ionotropic Receptors and NET Progression: N-Methyl-D-Aspartate Receptor

Ionotropic receptors are highly expressed and play key roles in different crucial aspects of the neuroendocrine cell physiology, ranging from excitation to synaptic release and gene expression. It is therefore not surprising that alteration of their function is involved in several hallmarks of NET progression.

Among the ionotropic receptors, N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor present in most excitatory neuronal synapses where it modulates synaptic plasticity with peculiar roles in learning and memory as well as neuron maturation. NMDAR is a nonselective Ca^{2+} -permeable channel also depicted as a “coincidence receptor” due to its voltage-dependent inhibition by Mg^{2+} [27]. The expression and functional activity of NMDAR has been reported in different cancer tissue and cell types such as small-cell lung cancer and breast cancer [28–30] or prostate cancer [31]. More recently, different research papers have implicated NMDAR in pancreatic neuroendocrine cancer (PNET) in vivo as well as in vitro [32]. The authors showed that NMDAR is upregulated in the periphery of PNET tumors, both in an Rip1-Tag2 mouse model and in human tissue microarrays [33]. Inhibition or downregulation of NMDAR but not AMPAR, another glutamate ionotropic receptor, significantly inhibits cell invasion. Interestingly, NMDAR is associated with vGlut family proteins, i.e., vesicular glutamate transporters that export glutamate in the presynaptic membrane to initiate the signals by activating postsynaptic membrane. The authors postulated that in PNET autocrine glutamate secretion is involved in their capability for invasion. More recently, this hypothesis has been strengthened by electrophysiological inhibition of autocrine-activated NMDAR activity by vGlut inhibitor treatment [32]. The activation of NMDAR signaling is followed by increased phosphorylation of calmodulin kinase type II and calmodulin kinase type IV, leading to a modest increase in CREB phosphorylation at Ser133. These data together with BAPTA-AM inhibition of NMDAR-mediated invasion, clearly showed a central

role of Ca^{2+} signaling in the process [33]. Interestingly Hanahan et al. [33] proposed an intriguing mechanism by which NMDAR in PNET cancer cells can hijack the glutamate-NMDAR signaling normally used by neurons to promote cell invasion via a cancer-specific mechanism. The authors hypothesized that the high interstitial fluid pressure (typical of solid tumors) and the consequent pressure drop at tumor margins activate glutamate release via a mechanosensory pathway. In turn, glutamate release promotes NMDAR activation with consequent intracellular Ca^{2+} -mediated signal transduction that promotes cell invasion.

Voltage-Gated Ca^{2+} Channels and NET Progression

A close correlation between voltage-gated Ca^{2+} channels and neuroendocrine differentiation (NED) has been extensively observed in prostate cancer [34, 35]. Indeed, the presence of neuroendocrine markers like CgA is correlated with prostate cancer dedifferentiation [36] and the presence of neuroendocrine cells in prostate cancer is correlated with a negative prognosis [37]. This is mainly due to the secretion of many neuropeptides with mitogenic activities like parathyroid hormone-related peptides, calcitonin, or gastrin-related peptides by neuroendocrine prostate cells which in turn could be responsible for the progression of cancer toward an androgen-independent stage. In this context, neuroendocrine prostate cancer cells overexpress a voltage-dependent calcium current of the T-type family, and in particular the channel subunit involved in this calcium current was shown to be the $\text{CaV}3.2$ ($\alpha 1\text{H}$) pore subunit [34]. This overexpression is attributable to upregulation of early growth response 1 and downregulation of repressor element (RE)-1- silencing transcription factor, which positively and negatively regulate transcriptional expression of $\text{CaV}3.2$, respectively [38]. Functional expression of $\text{CaV}3.2$ ($\alpha 1\text{H}$) sustains morphological differentiation and survival of neuroendocrine differentiated cells [39, 40]. Besides sustaining the NED of prostate cells, Ca^{2+} signals activated by ionomycin or thapsigargin treatments significantly promote secretion of prostatic acid phosphatase from NED. The specific role of $\text{CaV}3.2$ ($\alpha 1\text{H}$) was demonstrated by means of both pharmacological inhibitors or siRNA specifically directed against the channel. Both approaches show a clear involvement of $\text{CaV}3.2$ ($\alpha 1\text{H}$) in promoting both synthesis and secretion of prostatic acid phosphatase, and most likely serotonin, therefore being responsible of an enhanced autocrine/paracrine secretion in

neuroendocrine prostate cancer. This phenomenon has been suggested to be in turn responsible for the progression of prostate cancer toward an androgen-independent stage [35]. Because of their lower threshold for activation, T-type Ca^{2+} channel activity can be significant at membrane potentials close to rest, resulting in a “window current” and consequent basal Ca^{2+} entry that is likely to be responsible for the neuropeptide secretion, explaining the role of these channels even in the absence of action potential [35].

PNET cells (BON) express a different subset of voltage-gated Ca^{2+} channels which are involved in CgA release in BON cells or insulin release from insulinoma INS cell lines. In both cases the secretion relies in fact on R-type Cav ($\text{CaV}2.3$). This suggests a critical role in certain clinical characteristics of NET, such as hypersecretion syndrome [41]. Interestingly, $\text{CaV}2.3$ are also involved in somatostatin-mediated inhibitory mechanism of insulin release in pancreatic β cells. The activation of somatostatin receptor 2 significantly decreases $\text{CaV}2.3$ -mediated Ca^{2+} signals with a consequent inhibition of insulin release [42].

TRP Channels NET

The TRP family of channels encompasses 27 members of non-voltage-gated cation channels that are Ca^{2+} permeable though not selective for most of them [43]. Several TRP channels are deregulated in cancer cells and have been suggested as valuable markers in predicting cancer progression and as potential targets for pharmaceutical therapy [7, 44]. Concerning NET, TRP channels have been involved in neurosecretion and cell proliferation and in particular TRPM8, TRPV1, and TRPV6 in PNET BON cells lines as well as in primary PNET cells [45–47].

Cold/menthol-sensitive TRPM8 activation by icilin elicits $[\text{Ca}^{2+}]_i$ increases and secretion of neurotensin (NT) in BON cells as well as in primary PNET [45]. Interestingly NT is not expressed in the healthy pancreas, while its expression and secretion could be switched on during tumorigenesis of pancreatic endocrine cells. The release of NT could have a double physiopathological role: on one side NT is a potent stimulator for a number of secretion processes of the gastrointestinal tract and increased local and systemic levels of NT may contribute to hypersecretion characteristic of the carcinoid phenotype. On the other hand, NT have also been shown to sustain cell proliferation and enhanced tumor growth in different

in vitro and in vivo studies [48]. However, how the channel activation induces NT secretion should be further clarified. TRPM8 has been previously reported to participate in secretory pathways, in particular in cold-induced mucus hypersecretion of bronchial epithelial cells [49]. TRPM8-mediated airway mucus hypersecretion is induced by cold air in airway epithelial cells through the Ca^{2+} -PLC-PIP2-PKC-MARCKS signaling pathway. A secretory function has also been suggested for this channel in the prostate due to its localization in the epithelial cells on the apical side of the prostatic acini [50]. Even though this hypothesis was not further demonstrated, TRPM8 high expression was correlated with early prostate tumor progression while the channel expression decreases with tumor progression to the late, invasive, androgen-insensitive stage [for a review see 51]. In this context, it has emerged as an important factor in cell migration and prostate cancer progression, showing a protective role in metastatic prostate cancer due to its inhibition of cancer cell migration [52–55]. On the other hand, the short TRPM8 (sM8–18) isoform seems to have an opposite role, leading to an increase in prostate cancer cell migration and invasiveness through the activation of MMP-2 [56]. This effect could also result from sM8–18 inhibition of full-length TRPM8, as we have shown that the channel negatively regulates migration even if the interaction between short isoforms and ER-located TRPM8 has not yet been confirmed. In this respect, given the aggressiveness of NET it would be interesting to investigate which isoforms are expressed in NET and whether they affect cell migration in addition to NT secretion.

Beside TRPM8, TRPV1 is also implicated in neurosecretion in BON-1 PNET cells. In particular TRPV1 activation by capsaicin promotes CgA secretion, a common marker indicating hormone neuropeptide and biogenic amine release [57]. TRPV1-mediated CgA release could have some potential relevance for PNET physiopathology, considering the fact that TRPV1 activity is regulated by somatostatins which inhibit also CgA release [58]. It is easy to speculate that TRPV1 could be one of the mechanisms involved in CgA secretion as a target of somatostatin activity, which is an important therapeutic target for NET.

Finally, TRPV6 is expressed in several PNET cells, including BON-1, where it controls Ca^{2+} homeostasis. The presence of TRPV6 in neuroendocrine cancer cells mediates cell proliferation; TRPV6 downregulation reduces cell growth by approximately 30% and leads to a declined CCND1 and CDK4 expression without affecting CCND2. TRPV6-mediated cell proliferation is dependent on

NFAT- Ca^{2+} activation as shown by TRPV6 downregulation [47]. These data are in accordance with a previously reported role of TRPV6 in both prostate and breast cancer proliferation and growth. In particular TRPV6-mediated prostate cancer cell proliferation implicates NFAT activation [59].

Intracellular Ca^{2+} Signals in NET

The last paragraph of the present review is dedicated to a discussion of the role of intracellular Ca^{2+} signals in NET. We will analyze in particular the role of specific Ca^{2+} entry mechanisms triggered by the release from intracellular stores giving rise to SOCE or alternatively NSOCE mechanisms [11].

The role of Ca^{2+} homeostasis in NED has been clearly established in prostate cancer. As reported in previous paragraphs, in vitro NED differentiation is a poor prognosis marker in prostate cancer progression and it is frequently associated with androgen-independent states of cancer [37]. In vitro NED differentiation of the epithelial prostate LnCaP cell line induced by androgen depletion or [cAMP] increase causes marked changes in Ca^{2+} homeostasis including reduced filling of the ER Ca^{2+} store, decreased expression of both endolemmal SERCA 2b Ca^{2+} ATPase and the luminal Ca^{2+} binding/storage chaperone calreticulin, and a substantial downregulation of SOC current (I_{SOC}) [60]. The reduction of SOCE is due to cytoskeleton reorganization, especially F-actin over-polymerization [61]. As a final effect, SOCE downregulation in NE cells is involved in an increase in thapsigargin (Tg) or TNF α apoptosis resistance [60].

SOCE activation has also been described in different cell lines of GEP NET (GPNET). In particular SOCE-mediated Ca^{2+} signals can be recorded by exogenous store depletion by means of cyclopiazonic acid or muscarinic receptor activation by carbachol and are significantly inhibited by Gd $^{3+}$ 1 μM or BTP-2 perfusion. However, the authors did not describe any cellular function associated with SOCE [62].

Interestingly, recently NSOCE-mediated Ca^{2+} signals have been described in the GPNET cell line BON-1 after exogenous application of arachidonic acid (AA). From the molecular point of view, both ORAI1 and ORAI3 channels are required for AA-mediated Ca^{2+} signals. However, ORAI1 was necessary for mediation of SOCE, whereas ORAI1 and ORAI3 were both required for AA-induced Ca^{2+} entry as well as BON cell migration. Moreover, the activation of NSOCE by AA correlates with an

increase in BON-1 cell migration as well as induction of neuroendocrine mesenchymal transition [63]. These data are in accordance with previously reports showing that AA is a key player in cell migration [64, 65].

Conclusions

Even though few Ca^{2+} channels and their signaling molecules have been shown to be implicated in NET, they have constituted a growing field of interest in recent decades. Indeed, the expression of several channels from different families (ionotropic receptors and voltage-gated, TRP, and SOCE components) were shown to be deregulated in NET, thus mainly affecting neurosecretion, cell proliferation, neuroendocrine cell differentiation, and invasion mostly in GPNET. Interestingly the drivers of this deregulation are not the same for all channels analyzed. The role in NET progression is associated either with increased expression or with specific activation due to a peculiar tumor microenvironment. In this context, the link between a high intracellular interstitial pressure and a mechano-activated glutamate release, which in turn promotes NMDAR activation and Ca^{2+} -mediated cell invasion, as proposed by Hanahn et al. [33], is in fact quite intriguing. Therefore, the peculiar physical characteristics of the tumor microenvironment are responsible for NMDAR-specific activity in cancer cells. On the other hand, regarding the role of T-type Ca^{2+} channels in neuroendocrine prostate cancer cells, Mariot and colleagues described an upregulation of the $\text{CaV}3.2$ channel subunit αH1 in neuroendocrine differentiated LNCaP as compared with control (not differentiated) LNCaP [35]. Moreover, the marked changes in Ca^{2+} homeostasis observed in NED-differentiated LNCaP cells is due to cytoskeleton reorganization, especially F-actin overpolymerization as discussed by Prevarskaya and colleagues [61].

It would be interesting, though, to further characterize the molecular mechanisms underlying these cellular functions to carcinogenesis and investigate putative consequences in Ca^{2+} homeostasis. In this perspective, there have been several cases reports linking NET in the thymus, pancreas, and gastrointestinal tract to hypercalcemia [66, 67], suggesting that excessive hormone secretion influences Ca^{2+} channels and their signaling pathway. Increased serum Ca^{2+} levels in NET were mostly correlated with high 1,25-dihydroxyvitamin D and parathyroid hormone-related protein (PTH-rP) secretion. This link has to be further investigated since it is well known that 1,25-dihydroxyvitamin D and PTH regulate Ca^{2+} channel expression and in particular that of TRPV5 and TRPV6, both of which are involved in Ca^{2+} intestinal absorption, distal tubular reabsorption, and bone resorption [68].

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

The authors have no conflict of interests to declare.

Funding Sources

This study was supported by grants from the Ministère de l'Éducation Nationale and the Institut National de la Santé et de la Recherche Médicale (INSERM). The authors were supported by the Institut National du Cancer (INCa-PLBIO14-213). The research of D.G. was supported by the Fondation ARC pour la Recherche sur le Cancer (PJA 20141202010), the Association pour la Recherche sur les Tumeurs de la Prostate (ARTP), and the Institut Universitaire de France (IUF). A.F.P. was supported by grants from the University of Torino and the Compagnia di San Paolo (No. Torino_call2014_L2_130). D.G. was supported by the SFFR (F 46.2/001).

References

- 1 Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. *Endocr Relat Cancer*. 2010 Jan;17(1):R75–90.
- 2 Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. *Neoplasia*. 2017 Dec;19(12):991–1002.
- 3 Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: from monoanalyses to transcripts and algorithms. *Best Pract Res Clin Endocrinol Metab*. 2016 Jan;30(1):59–77.
- 4 Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. *Ann Surg*. 2007 Feb;245(2):273–81.
- 5 Wolin EM: The expanding role of somatostatin analogs in the management of neuroendocrine tumors. *Gastrointest Cancer Res*. 2012; 5:161–8.
- 6 Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al.; NETTER-1 Trial Investigators. Phase 3 Trial of ^{177}Lu -Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med*. 2017 Jan;376(2):125–35.
- 7 Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. *Nat Rev Cancer*. 2017 Jun;17(6):367–80.
- 8 Iamshanova O, Fiorio Pla A, Prevarskaya N. Molecular mechanisms of tumour invasion: regulation by calcium signals. *J Physiol*. 2017 May;595(10):3063–75.

- 9 Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol*. 2000 Oct;1(1):11–21.
- 10 Roderick HL, Cook SJ. Ca²⁺ signalling checkpoints in cancer: remodelling Ca²⁺ for cancer cell proliferation and survival. *Nat Rev Cancer*. 2008 May;8(5):361–75.
- 11 Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol*. 2003 Jul;4(7):517–29.
- 12 Szabó I, Lepple-Wienhues A, Kaba KN, Zoratti M, Gulbins E, Lang F. Tyrosine kinase-dependent activation of a chloride channel in CD95-induced apoptosis in T lymphocytes. *Proc Natl Acad Sci USA*. 1998;95:6169–74.
- 13 Arcangeli A, Becchetti A, Mannini A, Mugnai G, De Filippi P, Tarone G, et al. Integrin-mediated neurite outgrowth in neuroblastoma cells depends on the activation of potassium channels. *J Cell Biol*. 1993;122:1131–43.
- 14 Pardo LA, del Camino D, Sánchez A, Alves F, Brüggemann A, Beckh S, et al. Oncogenic potential of EAG K(+) channels. *EMBO J*. 1999 Oct;18(20):5540–7.
- 15 Skryma R, Mariot P, Bourhis XL, Coppenolle F V, Shuba Y, Vanden Abeele F, et al. Store depletion and store-operated Ca²⁺ current in human prostate cancer LNCaP cells: involvement in apoptosis. *J Physiol*. 2000;527:71–83.
- 16 Prevarskaya N, Skryma R, Shuba Y. Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? *Physiol Rev*. 2018 Apr;98(2):559–621.
- 17 Huber SM. Oncochannels. *Cell Calcium*. 2013 Apr;53(4):241–55.
- 18 Nanou E, Catterall WA. Calcium Channels, Synaptic Plasticity, and Neuropsychiatric Disease. *Neuron*. 2018 May;98(3):466–81.
- 19 Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. *Annu Rev Physiol*. 2006;68(1):619–47.
- 20 Cheng KT, Ong HL, Liu X, Ambudkar IS. Contribution of TRPC1 and Orail to Ca(2+) entry activated by store depletion. *Adv Exp Med Biol*. 2011;704:435–49.
- 21 Parekh AB, Putney JW Jr. Store-operated calcium channels. *Physiol Rev*. 2005 Apr;85(2):757–810.
- 22 Ong HL, de Souza LB, Zheng C, Cheng KT, Liu X, Goldsmith CM, et al. STIM2 enhances receptor-stimulated Ca²⁺ signaling by promoting recruitment of STIM1 to the endoplasmic reticulum-plasma membrane junctions. *Sci Signal*. 2015 Jan;8(359):ra3.
- 23 Ong HL, Subedi KP, Son GY, Liu X, Ambudkar IS. Tuning store-operated calcium entry to modulate Ca²⁺-dependent physiological processes. *Biochim Biophys Acta Mol Cell Res*. 2019 Jul;1866(7):1037–45.
- 24 Schindl R, Frischauf I, Bergsmann J, Muik M, Derler I, Lackner B, et al. Plasticity in Ca²⁺ selectivity of Orail/Orail3 heteromeric channel. *Proc Natl Acad Sci USA*. 2009 Nov;106(46):19623–8.
- 25 Moccia F, Zuccolo E, Soda T, Tanzi F, Guerra G, Mapelli L, et al. Stim and Orail proteins in neuronal Ca(2+) signaling and excitability. *Front Cell Neurosci*. 2015 Apr;9:153.
- 26 Kraft R. STIM and ORAI proteins in the nervous system. *Channels (Austin)*. 2015;9(5):245–52.
- 27 Cull-Candy S, Brickley S, Farrant M: NMDA receptor subunits: diversity, development and disease. *Curr Opin Neurobiol*. 2001;11:327–35.
- 28 Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Siffringer M, et al. Expression of glutamate receptor subunits in human cancers. *Histochem Cell Biol*. 2009 Oct;132(4):435–45.
- 29 North WG, Gao G, Memoli VA, Pang RH, Lynch L. Breast cancer expresses functional NMDA receptors. *Breast Cancer Res Treat*. 2010 Jul;122(2):307–14.
- 30 North WG, Gao G, Jensen A, Memoli VA, Du J. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. *Clin Pharmacol*. 2010;2:31–40.
- 31 Abdul M, Hoosein N. N-methyl-D-aspartate receptor in human prostate cancer. *J Membr Biol*. 2005 Jun;205(3):125–8.
- 32 Robinson HP, Li L. Autocrine, paracrine and necrotic NMDA receptor signalling in mouse pancreatic neuroendocrine tumour cells. *Open Biol*. 2017 Dec;7(12):170221.
- 33 Li L, Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. *Cell*. 2013 Mar;153(1):86–100.
- 34 Mariot P, Vanoverberghe K, Lalevée N, Rossier MF, Prevarskaya N. Overexpression of an α 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. *J Biol Chem*. 2002 Mar;277(13):10824–33.
- 35 Gackière F, Bidaux G, Delcourt P, Van Coppenolle F, Katsogiannou M, Dewailly E, et al. Cav3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells. *J Biol Chem*. 2008 Apr;283(15):10162–73.
- 36 Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. *Urology*. 2005 Oct;66(4):897–902.
- 37 Grobholz R, Griebel M, Sauer CG, Michel MS, Trojan L, Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. *Hum Pathol*. 2005 May;36(5):562–70.
- 38 Fukami K, Sekiguchi F, Yasukawa M, Asano E, Kasamatsu R, Ueda M, et al. Functional up-regulation of the H2S/Cav3.2 channel pathway accelerates secretory function in neuroendocrine-differentiated human prostate cancer cells. *Biochem Pharmacol*. 2015 Oct;97(3):300–9.
- 39 Weaver EM, Zamora FJ, Hearne JL, Martin-Caraballo M. Posttranscriptional regulation of T-type Ca(2+) channel expression by interleukin-6 in prostate cancer cells. *Cytokine*. 2015 Dec;76(2):309–20.
- 40 Hall M, Todd B, Allen ED, Nguyen N, Kwon Y-J, Nguyen V, et al.: Androgen receptor signaling regulates T-type Ca²⁺ channel expression and neuroendocrine differentiation in prostate cancer cells. *Am J Cancer Res*. 2018;8:732–47.
- 41 Mergler S, Wiedenmann B, Prada J. R-type Ca(2+)-channel activity is associated with chromogranin A secretion in human neuroendocrine tumor BON cells. *J Membr Biol*. 2003 Aug;194(3):177–86.
- 42 Mergler S, Singh V, Grötzinger C, Kaczmarek P, Wiedenmann B, Strowski MZ. Characterization of voltage operated R-type Ca²⁺ channels in modulating somatostatin receptor subtype 2- and 3-dependent inhibition of insulin secretion from INS-1 cells. *Cell Signal*. 2008 Dec;20(12):2286–95.
- 43 Montell C. The history of TRP channels, a commentary and reflection. *Pflugers Arch*. 2011 May;461(5):499–506.
- 44 Fiorio Pla A, Gkika D. Emerging role of TRP channels in cell migration: from tumor vascularization to metastasis. *Front Physiol*. 2013 Nov;4:311.
- 45 Mergler S, Strowski MZ, Kaiser S, Plath T, Giesecke Y, Neumann M, et al. Transient receptor potential channel TRPM8 agonists stimulate calcium influx and neurotensin secretion in neuroendocrine tumor cells. *Neuroendocrinology*. 2007;85(2):81–92.
- 46 Mergler S, Mertens C, Valtink M, Reinach PS, Székely VC, Slavi N, et al. Functional significance of thermosensitive transient receptor potential melastatin channel 8 (TRPM8) expression in immortalized human corneal endothelial cells. *Exp Eye Res*. 2013 Nov;116:337–49.
- 47 Skrzypski M, Kołodziejewski PA, Mergler S, Khajavi N, Nowak KW, Strowski MZ. TRPV6 modulates proliferation of human pancreatic neuroendocrine BON-1 tumour cells. *Biosci Rep*. 2016 Aug;36(4):e00372–00372.
- 48 Kim JT, Liu C, Zaytseva YY, Weiss HL, Townsend CM Jr, Evers BM. Neurotensin, a novel target of Wnt/ β -catenin pathway, promotes growth of neuroendocrine tumor cells. *Int J Cancer*. 2015 Mar;136(6):1475–81.
- 49 Li M, Li Q, Yang G, Kolosov VP, Perelman JM, Zhou XD. Cold temperature induces mucin hypersecretion from normal human bronchial epithelial cells in vitro through a transient receptor potential melastatin 8 (TRPM8)-mediated mechanism. *J Allergy Clin Immunol*. 2011 Sep;128(3):626–34.e1.
- 50 Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, et al. Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. *J Clin Invest*. 2007 Jun;117(6):1647–57.

- 51 Noyer L, Grolez GP, Prevarskaya N, Gkika D, Lemonnier L. TRPM8 and prostate: a cold case? *Pflugers Arch*. 2018 Oct;470(10):1419–29.
- 52 Gkika D, Lemonnier L, Shapovalov G, Gordienko D, Poux C, Bernardini M, et al. TRP channel-associated factors are a novel protein family that regulates TRPM8 trafficking and activity. *J Cell Biol*. 2015 Jan;208(1):89–107.
- 53 Gkika D, Flourakis M, Lemonnier L, Prevarskaya N. PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression. *Oncogene*. 2010 Aug;29(32):4611–6.
- 54 Yang ZH, Wang XH, Wang HP, Hu LQ. Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. *Asian J Androl*. 2009 Mar;11(2):157–65.
- 55 Zhu G, Wang X, Yang Z, Cao H, Meng Z, Wang Y, et al. Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo. *Oncol Lett*. 2011 Nov;2(6):1213–7.
- 56 Peng M, Wang Z, Yang Z, Tao L, Liu Q, Yi LU, et al. Overexpression of short TRPM8 variant α promotes cell migration and invasion, and decreases starvation-induced apoptosis in prostate cancer LNCaP cells. *Oncol Lett*. 2015 Sep;10(3):1378–84.
- 57 Mergler S, Skrzypski M, Sassek M, Pietrzak P, Pucci C, Wiedenmann B, et al. Thermo-sensitive transient receptor potential vanilloid channel-1 regulates intracellular calcium and triggers chromogranin A secretion in pancreatic neuroendocrine BON-1 tumor cells. *Cell Signal*. 2012 Jan;24(1):233–46.
- 58 Carlton SM, Zhou S, Du J, Hargett GL, Ji G, Coggeshall RE. Somatostatin modulates the transient receptor potential vanilloid 1 (TRPV1) ion channel. *Pain*. 2004 Aug;110(3):616–27.
- 59 Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via $\text{Ca}(2+)/\text{NFAT}$ -dependent pathways. *Oncogene*. 2007 Nov;26(52):7380–5.
- 60 Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, et al. Ca^{2+} homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. *Cell Death Differ*. 2004 Mar;11(3):321–30.
- 61 Vanoverberghe K, Lehen'kyi V, Thébault S, Raphaël M, Vanden Abeele F, Slomianny C, et al. Cytoskeleton reorganization as an alternative mechanism of store-operated calcium entry control in neuroendocrine-differentiated cells. *PLoS One*. 2012;7(9):e45615.
- 62 Arunachalam S, Zhelay T, Giovannucci DR: Molecular and functional characterization of non voltage-operated Ca entry in gastrointestinal neuroendocrine tumor cells. *Int J Physiol Pathophysiol Pharmacol*. 2010;2:125–36.
- 63 Goswamee P, Pounardjian T, Giovannucci DR. Arachidonic acid-induced Ca^{2+} entry and migration in a neuroendocrine cancer cell line. *Cancer Cell Int*. 2018 Mar;18(1):30.
- 64 Fiorio Pla A, Grange C, Antoniotti S, Tomatis C, Merlino A, Bussolati B, et al. Arachidonic acid-induced Ca^{2+} entry is involved in early steps of tumor angiogenesis. *Mol Cancer Res*. 2008 Apr;6(4):535–45.
- 65 Fiorio Pla A, Genova T, Pupo E, Tomatis C, Genazzani A, Zaninetti R, et al. Multiple roles of protein kinase a in arachidonic acid-mediated Ca^{2+} entry and tumor-derived human endothelial cell migration. *Mol Cancer Res*. 2010 Nov;8(11):1466–76.
- 66 Brzozowska MM, Wolmarans L, Conaglen JV. Hypercalcaemia caused by a carcinoid tumour. *Intern Med J*. 2009 Jun;39(6):415–8.
- 67 Shah RH, Martinez D. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature. *Pancreas*. 2013 Apr;42(3):549–51.
- 68 van Goor MK, Hoenderop JG, van der Wijk J. TRP channels in calcium homeostasis: from hormonal control to structure-function relationship of TRPV5 and TRPV6. *Biochim Biophys Acta Mol Cell Res*. 2017 Jun;1864(6):883–93.